None listed
Conditions
Brief summary
Australia has an ageing population and muscle loss (also known as sarcopenia) is a common condition amongst older adults and is a natural part of the ageing process. Progressive loss of muscle increases the risk of fractures and lowers life expectancy, quality of life as well as limited ability to perform daily tasks with greater levels of fatigue and exhaustion. Changes in the immune system associated with ageing have also been suggested as potential contributing factors to muscle loss and physical frailty. Adequate nutritional intake as well as resistance/balance exercise training and some pharmacological intervention are the current preventative and therapeutic strategies for sarcopenia, however, long-term adherence to complex lifestyle changes that are also physically demanding can be a barrier for some individuals. Therefore, a safe, effective, adjunct therapy with potentially multiple health benefits may improve the well-being of older adults to delay or prevent further muscle loss and potentially improve muscle mass, strength, quality of life and physical function. This study aims to evaluate the health benefits of a dietary supplement containing pine bark extract in healthy older adults. Collection of information and measurements from you will enable us to investigate the health effects of this dietary supplement in older adults to promote healthy ageing.
Interventions
The effects of an oral liquid supplement containing 1350mg pinus massoniana extract each day compared to placebo. This double-blinded, randomised controlled trial is a two-armed parallel placebo-controlled design.
Healthy adult individuals will be randomly assigned to consume one of the following everyday for 12 weeks:
Placebo: 50mL oral liquid supplement containing no Pinus Massoniana
Active: 50mL oral liquid supplement containing 1350mg Pinus Massoniana
*Pinus Massoniana (known as Masson pin
The effects of an oral liquid supplement containing 1350mg pinus massoniana extract each day compared to placebo. This double-blinded, randomised controlled trial is a two-armed parallel placebo-controlled design. Healthy adult individuals will be randomly assigned to consume one of the following everyday for 12 weeks: Placebo: 50mL oral liquid supplement containing no Pinus Massoniana Active: 50mL oral liquid supplement containing 1350mg Pinus Massoniana *Pinus Massoniana (known as Masson pine or Chinese red pine) will be delivered as the commercially available RecoveR8 liquid supplement which has been approved by the TGA as a 'Single Medicine Product' product type. Participants will be instructed how to consume the study product at their initial baseline visit to the research clinic. The liquid supplement is to be consumed with a meal, preferably breakfast (as part of their habitual diet). To assess compliance: 1. Participants will be asked to record their daily consumption of the liquid supplement in a standardised log provided to them. 2. Participants will be asked to return all supplement bottles both empty as well as any bottles containing un-consumed product.
Sponsors
University of Newcastle
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
• Healthy adults aged 55 to 75 years old without existing chronic diseases • Gender: both males and females
Exclusion criteria
• Diagnosed chronic diseases and/or are being treated for chronic diseases e.g. cardiovascular disease, cancer, type 2 diabetes, chronic kidney disease, liver failure, pancreatitis, inflammatory bowel disease etc • Currently taking any medication and/or supplements known to have anti-inflammatory, antioxidant, blood pressure-lowering, immunosuppressant or anticoagulant effects • Recently commenced a dietary intervention in the past 3 months or made significant changes to their dietary patterns, food choices, lifestyle and/or physical activity levels in the past 3 months • Allergic or intolerant to figs, kiwifruit and papaya • Pregnant or breast-feeding
Outcome results
None listed